Vertex Pharmaceuticals (VRTX) Share-based Compensation (2009 - 2026)

Vertex Pharmaceuticals has reported Share-based Compensation for 18 years, with the latest figure at $166.4 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation changed 0.18% year-over-year to $166.4 million; the trailing twelve-month figure through Mar 2026 stood at $686.2 million (up 2.01% YoY), and the FY2025 full-year result was $685.9 million, down 1.8% from the prior year.
• Share-based Compensation for Q1 2026 stood at $166.4 million, up from $157.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $208.6 million in Q4 2023, with the low at $111.5 million in Q4 2022.
• Average Share-based Compensation over 5 years is $154.3 million, with a median of $157.6 million recorded in 2025.
• Year-over-year, Share-based Compensation jumped 87.09% in 2023 and fell 19.56% in 2024.
• Tracing VRTX's Share-based Compensation over 5 years: stood at $111.5 million in 2022, then soared by 87.09% to $208.6 million in 2023, then slipped by 19.56% to $167.8 million in 2024, then declined by 6.08% to $157.6 million in 2025, then advanced by 5.58% to $166.4 million in 2026.
• The last three Share-based Compensation figures came in at $166.4 million (Q1 2026), $157.6 million (Q4 2025), and $194.9 million (Q3 2025), per Business Quant data.

Peer Comparison